Cantor Fitzgerald Initiates Coverage on Atyr PHARMA (NASDAQ:ATYR)

Cantor Fitzgerald started coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note issued to investors on Monday morning, MarketBeat Ratings reports. The firm issued an overweight rating on the stock.

Several other research analysts have also recently issued reports on the company. Wells Fargo & Company assumed coverage on Atyr PHARMA in a research report on Friday, October 4th. They issued an “overweight” rating and a $17.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $19.25.

Atyr PHARMA Stock Down 0.3 %

ATYR stock opened at $3.97 on Monday. The company has a market cap of $333.25 million, a price-to-earnings ratio of -4.22 and a beta of 1.08. The company’s 50 day moving average is $3.30. Atyr PHARMA has a twelve month low of $1.39 and a twelve month high of $4.23. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR) last issued its earnings results on Thursday, November 7th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.01). On average, research analysts expect that Atyr PHARMA will post -0.89 earnings per share for the current fiscal year.

Institutional Trading of Atyr PHARMA

An institutional investor recently raised its position in Atyr PHARMA stock. JPMorgan Chase & Co. increased its position in shares of Atyr PHARMA INC (NASDAQ:ATYR) by 52.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,440 shares of the company’s stock after purchasing an additional 10,754 shares during the period. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 at the end of the most recent quarter. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.